Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, that develops treatments for serious diseases. It has a diversified pre-clinical pipeline that encompasses investigational candidates targeted at the treatment, cancer, and hematologic diseases. The company operates through one operating segment, which includes development and commercializing of genome editing technology. The company’s pipeline products includes reni-cel, EDIT- -301, that pursue next-generation in vivo gene editing medicines targeting hematopoietic stem cells. It is also focuses on development of in vivo gene editing medicines for other organs and tissues. Other products are based on therapy areas including Autosomal Dominant Retinitis Pigmentosa 4 and Alpha-Beta T Cells. Reni-cel formerly known as EDIT-301, an engineered cell medicines for treatment of Sickle Cell disease and Beta-thalassemia.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The R&D activities focuses on the development and commercialization of products that complement and update its existing product offerings. The company’s focuses on gene editing medicines: in vivo gene editing medicines for inside the body and ex vivo gene editing medicines which occurs outside the body to create edited cell medicines. Editas Medicine focuses in two different CRISPR nucleases: Cas9 and Cas12a, also referred to as Cpf1. Each nuclease possesses unique gene editing functionalities and targeting potentials. It also aims on hematology, oncology and other organs and tissues. In FY2023, the company incurred research and development (R&D) expense of US$177.6 million as compared to US$174.9 million, representing a growyyh of 1.5% and 130 employees working towards R&D Activities. It works in collaboration with Allergan and Bristol Myers Squibb to discover and develop its pipeline products. As of December 2023, the company had 31 US patents, 74 pending US non-provisional patent applications, 16 European patents and related validations, 62 pending European patent applications, four pending US provisional patent applications, nine pending PCT patent applications, and other related patent applications in the US and Europe that are related to the CRISPR technology.